Angela Mastronuzzi: Our Ospedale Pediatrico Bambino Gesù team’s recently published paper with Nature Communications by Nature Portfolio is out.

Angela Mastronuzzi, Head of Neuro-Oncology Unit at Bambino Gesù Children’s Hospital, recently posted on LinkedIn:

“Our Ospedale Pediatrico Bambino Gesù team’s recently published paper with Nature Communications by Nature Portfolio is out:

Chimeric antigen receptor T (CAR-T) cell therapy may achieve long-lasting remission in patients with B-cell malignancies not responding to conventional therapies. Here we present a comprehensive humanized mouse model, by which we show that IFNγ neutralization by the clinically approved monoclonal antibody, emapalumab, mitigates severe toxicity related to CART cell therapy.

We demonstrate that emapalumab reduces the pro-inflammatory environment in the model, thus allowing control of severe CRS and preventing brain damage, characterized by multifocal hemorrhages.

Importantly, our in vitro and in vivo experiments show that IFNγ inhibition does not affect the ability of CD19-targeting CAR-T (CAR.CD19-T) cells to eradicate CD19+ lymphoma cells.

Simona Manni, Francesca Del Bufalo, Pietro Merli, Marika Guercio, Simona Caruso, Sofia Reddel, Laura Iaffaldano, Michele Pezzella, Stefano Di Cecca, Matilde Sinibaldi, Alessio Ottaviani, Maria Cecilia Quadraccia, Concetta Quintarelli, Biagio De Angelis, Maria Pia Cefalo, Rita De Vito, Roselia Ciccone, Andrea Sarcinelli.”

Source: Angela Mastronuzzi/LinkedIn